Navigation Links
Sanofi-aventis Stands Behind the Safety of Lantus(R)
Date:6/26/2009

BRIDGEWATER, N.J., June 26 /PRNewswire-FirstCall/ -- Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) has just been made aware of data associated with a retrospective follow-up of four patient registries. The results of these data clearly show that no definitive conclusions can be drawn regarding a possible causal relationship between Lantus(R) (insulin glargine [rDNA] injection) use and the occurrence of malignancies, as the authors of the study point out.

Clinical studies, which represent the gold standard of evidence, do not indicate an association between insulin glargine and cancer.

"Given the extensive clinical evidence covering over 70,000 patients and the results of post-marketing surveillance arising from 24 million patient-years of experience, sanofi-aventis stands behind the safety of Lantus(R)," said Jean-Pierre Lehner, M.D., Chief Medical Officer. "We consider that the results of these patient registries are not conclusive."

Patient safety is the primary concern of sanofi-aventis. The Group will continue to vigorously monitor the safety of Lantus(R) in close collaboration with regulatory agencies and scientific experts.

About Diabetes

Diabetes is a chronic, widespread condition in which the body does not produce or properly use insulin, the hormone needed to transport glucose (sugar) from the blood into the cells of the body for energy. More than 230 million people worldwide are living with the disease and this number is expected to rise to a staggering 350 million within 20 years. It is estimated that nearly 24 million Americans have diabetes, including an estimated 5.7 million who remain undiagnosed. At the same time, approximately 40 percent of those diagnosed are not achieving the blood sugar control target of HbA1c <7 percent recomme
'/>"/>

SOURCE sanofi-aventis
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Insulin Analogues From Novo Nordisk, Eli Lilly and Sanofi-Aventis Will Drive Growth in the Type 1 Diabetes Drug Market
2. Vical Licensee Sanofi-aventis Initiates Phase 3 Trial to Reduce Amputations
3. Kibow Biotech Obtains Australian, Chinese and Indian Patents Protecting the Composition and Basic Technology Behind Its Oral Probiotic Formulation for Chronic Kidney Failure
4. Cleveland Clinic Researchers Identify Mechanism Behind Platelet Function and Potentially Fatal Blood Clot Formation
5. New Safety Regulations Drive Greater Need for Resources and Expertise at Every Stage of Clinical Development
6. Study Results Present Efficacy and Safety Findings from the PHIRST-1 Study of Patients with Pulmonary Arterial Hypertension Taking Tadalafil Tablets Once Daily
7. AFRESA(R) Phase 3 Pulmonary Function Safety Data in Patients with Diabetes Presented at ADA
8. Researchers Present Safety and Efficacy Results of 429 Patients Treated With Radiofrequency Ablation for Pre-Cancerous Barretts Esophagus
9. Living Donor Kidney Transplants Using Alemtuzumab Pre-Conditioning and Tacrolimus Monotherapy: Long-Term Safety and Efficacy
10. Results and Additional Analyses From Efficacy and Safety Study of Cortheras Relaxin in Acute Heart Failure to be Presented at Heart Failure Congress 2009
11. VIVUS Initiates Open Label Safety Study of Avanafil for Erectile Dysfunction
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... , Sept. 18, 2014  Neurotrope, Inc. (OTCQB: NTRP) ... , M.D., Ph.D. to the Company,s Board of Directors, ... fills a vacancy on the Board of seven members. ... and Corporate Governance Committee and a member of the ... a member of Neurotrope,s Scientific Advisory Board, a position ...
(Date:9/18/2014)... , September 18, 2014 After ... chain community, we,re finally here - the new programme for ... January 2015, part of our global Cool Chain series, has ... here ! As the lines between supply ... put together a programme that is broad and yet specific, ...
(Date:9/18/2014)... Relmada Therapeutics, Inc., (OTCQB: RLMD), a clinical-stage ... pain, announced today that it has appointed Mr. ... Director of Clinical Development. During his extensive ... led successful global clinical operations teams, in the US ... clinical development of numerous therapeutics and diagnostics across a ...
Breaking Medicine Technology:Larry D. Altstiel, M.D., Ph.D. Joins Neurotrope Board of Directors 2Larry D. Altstiel, M.D., Ph.D. Joins Neurotrope Board of Directors 3Larry D. Altstiel, M.D., Ph.D. Joins Neurotrope Board of Directors 4Europe's Biggest and Longest-Running Gathering of Life Sciences Logistics, Supply Chain & QA Professionals 2Relmada Therapeutics, Inc. Appoints Christopher W. James As Senior Director of Clinical Development 2
... 2011 Nationally-acclaimed researcher and award-winning author Dr. Cynthia ... National Conference on Cancer Nursing Research that silver treated ... were supposed to prevent. After testing ... with silver coated or silver impregnated fluid pathway components, ...
... Pharmaceuticals, Inc. (Nasdaq: OPTR ) today announced the ... shares of its common stock, offered at a price to ... Optimer from this offering are expected to be $67.5 million, ... offering expenses payable by Optimer.  The offering is expected to ...
Cached Medicine Technology:Instead of Preventing Infections, Silver Coated Needleless IV Connectors May Actually Cause Them, a Nationally-Recognized Expert Tells National Conference on Cancer Nursing Research 2Optimer Pharmaceuticals, Inc. Prices Public Offering of Common Stock 2Optimer Pharmaceuticals, Inc. Prices Public Offering of Common Stock 3
(Date:9/19/2014)... Abilene, Texas (PRWEB) September 19, 2014 Yisrayl ... article this week expounding on the need to protect children. ... took place with Michael Brown and reminds that there are ... and victimized. Yisrayl says violence is spreading faster than cancer ... character training. , “There are close to seven billion Michaels ...
(Date:9/18/2014)... (PRWEB) September 19, 2014 Today, Zane ... information on why to switch employees to individual health ... employees may be more familiar with traditional, group health ... that makes employees happier. , The new article ... with individual health insurance rather than group health insurance, ...
(Date:9/18/2014)... WA (PRWEB) September 18, 2014 Kent, ... Lake Meridian Chiropractic are pleased to announce that Dawn Kelly ... 24-year-old clinic. Dr. Saggau looks forward to Ms. Kelly ... and administrative talents will make her a key contributor. ... combination of educational, professional, and personal experiences that will ...
(Date:9/18/2014)... (PRWEB) September 19, 2014 A jacket ... body. A jacket typically has sleeves, and fastens in ... is generally lighter, tighter-fitting, and less insulating than a ... others serve as protective clothing. Today, Fecbek, a well-known ... arrivals of trendy men’s jackets; all these items are ...
(Date:9/18/2014)... 2014 "Medical staff need better ways ... maintaining the patient's privacy," said one of two inventors ... in order to supply caregivers with the equipment they ... a prototype for The Helper to make it easier ... turn patient onto his or her side. It also ...
Breaking Medicine News(10 mins):Health News:Yisrayl Hawkins Says the Michael Brown Scenario Will Continue Without Swift Action in New Post 2Health News:Zane Benefits Publishes New Information on Why Employees Are Happier with Individual Health Insurance 2Health News:Lake Meridian Chiropractic of Kent, WA Announces that Dawn Kelly Has Been Promoted to the Position of Office Manager 2Health News:Cool Jackets Are For Sale At Fecbek.com 2
... America, Inc., a leading medical diagnostic instrument manufacturer ... of Jim Cusack as Director of Business Development ... of Marketing & Medical Affairs, Sysmex America. ... the company,s existing business partnerships and in identifying ...
... 10 Surfers, cancer survivors and supporters ... Pacific Ocean with a special purpose: to show their support for ... Survivor Beach, they will place their surfboards in the sand, one-by-one, ... surfboards. The line will start at Scripps Pier and continue ...
... Boston University School of Medicine (BUSM) and collaborators have ... ,EUK-400 series, which could someday be used to prevent ... brains of radiological terrorism victims. The findings, which appear ... Biological Inorganic Chemistry , describe new agents which can ...
... "Help is Here Express" bus tour will be stopping in ... various cities in order to help uninsured and financially-struggling Iowans ... or nearly free. With the state,s unemployment rate now hitting ... Partnership for Prescription Assistance (PPA) is ready to help state ...
... 10 Caraco Pharmaceutical Laboratories, Ltd. (NYSE Amex: ... settlement of the legal proceedings related to Lexapro(R) (escitalopram ... with Forest Laboratories, Inc. ("Forest") to acquire several products ... litigation settlement resolves litigation involving Caraco, Forest, Forest Holdings, ...
... today that the U.S. Food and Drug Administration (FDA) ... industry,s first programmable bone conduction hearing solution. The Baha ... adults with conductive hearing loss, mixed hearing loss or ... BP100 improves upon previous systems by offering users the ...
Cached Medicine News:Health News:Sysmex America Names Industry Veteran to Business Development Post 2Health News:Moores UCSD Cancer Center Luau and Longboard Invitational Hosts Survivor Beach Aug. 9 2Health News:Moores UCSD Cancer Center Luau and Longboard Invitational Hosts Survivor Beach Aug. 9 3Health News:New oral agents may prevent injury after radiation exposure 2Health News:Partnership for Prescription Assistance Prepared to Help Iowa Workers Hurt by Recession 2Health News:Partnership for Prescription Assistance Prepared to Help Iowa Workers Hurt by Recession 3Health News:Partnership for Prescription Assistance Prepared to Help Iowa Workers Hurt by Recession 4Health News:Caraco Pharmaceutical Laboratories, Ltd. Enters Into Asset Purchase Agreement with Forest Laboratories, Inc. to Settle Lexapro(R) (escitalopram oxalate) ANDA Patent Litigation 2Health News:Cochlear Americas Announces FDA Clearance of the Cochlear(TM) Baha(R) BP100 Sound Processor, the Industry's First Programmable Bone Conduction Hearing Solution 2Health News:Cochlear Americas Announces FDA Clearance of the Cochlear(TM) Baha(R) BP100 Sound Processor, the Industry's First Programmable Bone Conduction Hearing Solution 3
... Pens-Using a proprietary and patented technology, ADI ... called Antigen-Antibody pens-TM, that will allow researchers ... in any form or shape or size. ... to see antigen being written on the ...
... Antigen-Antibody Pens-Using a proprietary and patented technology, ... pens, called Antigen-Antibody pens-TM, that will allow ... membranes in any form or shape or ... helps to see antigen being written on ...
... Pens-Using a proprietary and patented technology, ADI ... called Antigen-Antibody pens-TM, that will allow researchers ... in any form or shape or size. ... to see antigen being written on the ...
... 350 Liters of pure water, Complete, Compact ... Purified Water,Millipores compact S.D.S. Storage and Distribution ... 350 liters of purified water produced by ... consistent purity of stored water, provide effective ...
Medicine Products: